A therapeutic trial of milacemide in myoclonus and the stiff-person syndrome.
We investigated the therapeutic effects of milacemide in seven patients with myoclonus and three patients with the stiff-person syndrome in an open-label trial. Milacemide was initiated at 800 mg/day and was gradually increased to a maximum dosage of 2,400 mg/day. No significant improvement occurred in the 10 patients.
Brown
P
P
MRC Human Movement and Balance Unit, Institute of Neurology, London, England.
Thompson
P D
PD
Rothwell
J C
JC
Day
B L
BL
Marsden
C D
CD
D000081:Acetamides / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000927:Anticonvulsants; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors; D009127:Muscle Rigidity / Q000188:drug therapy*; D009207:Myoclonus / Q000188:drug therapy*; D009460:Neurologic Examination; D013035:Spasm / Q000188:drug therapy; D013577:Syndrome
D000081:Acetamides; D000927:Anticonvulsants; D008996:Monoamine Oxidase Inhibitors; C039332:milacemide